Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2001-2-22
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antipsychotic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cholinergic Agonists, http://linkedlifedata.com/resource/pubmed/chemical/DRD4 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Dopamine Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Drd4 protein, mouse, http://linkedlifedata.com/resource/pubmed/chemical/Enzyme Inhibitors, http://linkedlifedata.com/resource/pubmed/chemical/Excitatory Amino Acid Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/Nitric Oxide Synthase, http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Serotonin, 5-HT2A, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, AMPA, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D2, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Dopamine D4, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Metabotropic Glutamate, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, N-Methyl-D-Aspartate, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Neurotensin, http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Serotonin, http://linkedlifedata.com/resource/pubmed/chemical/Serotonin Antagonists, http://linkedlifedata.com/resource/pubmed/chemical/neurotensin type 1 receptor
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0022-2623
pubmed:author
pubmed:issnType
Print
pubmed:day
15
pubmed:volume
44
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
477-501
pubmed:dateRevised
2005-11-17
pubmed:meshHeading
pubmed-meshheading:11170639-Animals, pubmed-meshheading:11170639-Antipsychotic Agents, pubmed-meshheading:11170639-Cholinergic Agonists, pubmed-meshheading:11170639-Disease Models, Animal, pubmed-meshheading:11170639-Dopamine Antagonists, pubmed-meshheading:11170639-Enzyme Inhibitors, pubmed-meshheading:11170639-Excitatory Amino Acid Antagonists, pubmed-meshheading:11170639-Humans, pubmed-meshheading:11170639-Mice, pubmed-meshheading:11170639-Mice, Transgenic, pubmed-meshheading:11170639-Nitric Oxide Synthase, pubmed-meshheading:11170639-Receptor, Serotonin, 5-HT2A, pubmed-meshheading:11170639-Receptors, AMPA, pubmed-meshheading:11170639-Receptors, Dopamine D2, pubmed-meshheading:11170639-Receptors, Dopamine D4, pubmed-meshheading:11170639-Receptors, Metabotropic Glutamate, pubmed-meshheading:11170639-Receptors, N-Methyl-D-Aspartate, pubmed-meshheading:11170639-Receptors, Neurotensin, pubmed-meshheading:11170639-Receptors, Serotonin, pubmed-meshheading:11170639-Schizophrenia, pubmed-meshheading:11170639-Serotonin Antagonists
pubmed:year
2001
pubmed:articleTitle
Current and novel approaches to the drug treatment of schizophrenia.
pubmed:affiliation
Merck Sharp and Dohme, The Neuroscience Research Centre, Terlings Park, Eastwick Road, Harlow, Essex CM20 2QR, UK. Michael_Rowley@Merck.com
pubmed:publicationType
Journal Article, Review